← Back to Search

Mesenchymal Stromal Cells

Adipose Derived MSCs for Osteoarthritis

Phase 1
Recruiting
Led By Aaron J Krych
Research Sponsored by Mayo Clinic
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up for a period of 2 years following last injection
Awards & highlights

Study Summary

This trial is testing whether a certain type of injection is safe and effective for treating hip pain caused by arthritis.

Who is the study for?
This trial is for adults aged 18-65 with chronic hip osteoarthritis (OA) pain, who've tried conservative treatments without surgery plans for the next year. Participants must be able to walk unassisted and agree to use contraception if of childbearing potential. Exclusions include pregnancy, allergies to study drugs, recent injections in the target hip, BMI over 35, certain medication use, infectious diseases like HIV or hepatitis, history of cancer except some skin cancers, drug abuse or significant cardiovascular and other systemic diseases.Check my eligibility
What is being tested?
The trial tests whether injecting a patient's own cultured adipose-derived mesenchymal stromal cells (AMSCs) into their painful hip can safely relieve OA pain and which dose works best. It involves fat harvesting from participants followed by laboratory cell expansion before injection back into the affected hip joint.See study design
What are the potential side effects?
Potential side effects may include reactions at the injection site such as pain or swelling, infection risk due to invasive procedures involved in fat harvesting and injections. There might also be general risks associated with cell therapies including immune system reactions.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~for a period of 2 years following last injection
This trial's timeline: 3 weeks for screening, Varies for treatment, and for a period of 2 years following last injection for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Nature, incidence and severity of adverse events (AEs)
Secondary outcome measures
Change in Hip disability and osteoarthritis Outcome Score (HOS) in the target hip following completion of treatment cycles
Change in Tegner activity scale in the target hip following completion of treatment cycles
Change in Visual Analog Scale (VAS) for pain in the target hip following completion of treatment cycles
+8 more

Trial Design

2Treatment groups
Experimental Treatment
Group I: Two InjectionsExperimental Treatment1 Intervention
Two-dose administration (2 x ultrasound guided injections) of Autologous Adipose Derived Mesenchymal Stromal Cells into the hip with one month interval between doses
Group II: Single InjectionExperimental Treatment1 Intervention
Single administration of Autologous Adipose Derived Mesenchymal Stromal Cells into the hip by single ultrasound guided injection

Find a Location

Who is running the clinical trial?

Mayo ClinicLead Sponsor
3,207 Previous Clinical Trials
3,767,116 Total Patients Enrolled
29 Trials studying Osteoarthritis
2,850 Patients Enrolled for Osteoarthritis
Aaron J KrychPrincipal InvestigatorMayo Clinic
2 Previous Clinical Trials
275 Total Patients Enrolled

Media Library

Autologous Adipose Derived Mesenchymal Stromal Cells (Mesenchymal Stromal Cells) Clinical Trial Eligibility Overview. Trial Name: NCT03608579 — Phase 1
Osteoarthritis Research Study Groups: Single Injection, Two Injections
Osteoarthritis Clinical Trial 2023: Autologous Adipose Derived Mesenchymal Stromal Cells Highlights & Side Effects. Trial Name: NCT03608579 — Phase 1
Autologous Adipose Derived Mesenchymal Stromal Cells (Mesenchymal Stromal Cells) 2023 Treatment Timeline for Medical Study. Trial Name: NCT03608579 — Phase 1

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

How many participants are currently enrolling in this clinical exploration?

"Affirmative. Information published on clinicaltrials.gov attests that this medical research is now looking for participants - it was first launched on the 5th of November 2018 and last updated on December 2nd 2022. 24 volunteers need to be recruited from one trial centre."

Answered by AI

Are recruitment efforts underway to include participants in this research?

"Affirmative. According to clinicaltrials.gov, this trial is actively enrolling participants at present and was initially posted on the 5th of November 2018 before being updated most recently on 2nd December 2022. A total of 24 patients need to be recruited from one site in particular."

Answered by AI

Are individuals who are 25 years or older eligible for participation in this trial?

"This study is onboarding participants of legal age and under 65 years old."

Answered by AI

What criteria must be satisfied in order to enroll in this research program?

"This clinical trial, which is recruiting approximately 24 patients, requires all participants to have osteoarthritis of the hip and be aged 18-65."

Answered by AI

Is Autologous Adipose Derived Mesenchymal Stromal Cells a secure option for individuals?

"Autologous Adipose Derived Mesenchymal Stromal Cells have been assigned a safety rating of 1 due to the fact that this is still an early phase trial, with restricted evidence pointing toward its efficacy and security."

Answered by AI

Who else is applying?

What state do they live in?
Arizona
How old are they?
18 - 65
What site did they apply to?
Mayo Clinic in Rochester
What portion of applicants met pre-screening criteria?
Met criteria
~2 spots leftby Nov 2024